• X Zhang, Y Dong, F Tang, F Zhang, and H Li.
• Department of Rheumatology, PUMC Hospital, CAMS, PUMC, Beijing 100730, China. zhangxuan@csc.pumch.ac.cn
• Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2000 Feb 1; 22 (1): 82-4.

ObjectiveTo study the effect of high dose intravenous immunoglobulins(IvIg) in systemic lupus erythematosus (SLE)-associated thrombocytopenia.MethodsA case-control study was undertaken to assess the effectiveness of different therapeutic regimens (oral prednisone, IvIg, bolus methylprednisolone(MP), and IvIg plus bolus MP) in improving SLE-associated thrombocytopenia.ResultsFor SLE-associated thrombocytopenia, IvIg, bolus MP, and IvIg plus bolus IvIg significantly shorten the time to reach a peak platelet count, which was (6.2 +/- 4.4) days, (7.3 +/- 4.9) days, and (3.8 +/- 2.4) days respectively in comparison with oral prednisone, which was (31.0 +/- 17.8) days (P< 0.01); if high dose IvIg and MP in combination, the time was also shorter than bolus MP alone (P < 0.05). The elevation of platelet count in groups receiving IvIg, bolus MP, and IvIg plus bolus MP were significantly higher than as in group receiving oral prednisone therapy(P < 0.05).ConclusionsHigh dose IvIg is a useful therapy in improving SLE-associated thrombocytopenia.

17 keywords...

hide…